Equillium (EQ) Competitors $0.35 +0.00 (+0.52%) Closing price 07/11/2025 03:40 PM EasternExtended Trading$0.35 0.00 (-0.86%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. MDCX, NBRV, APLT, PLUR, PRLD, MURA, ATNM, SCLX, GRCE, and XCURShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Medicus Pharma Nabriva Therapeutics Applied Therapeutics Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Grace Therapeutics Exicure Medicus Pharma (NASDAQ:MDCX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Does the media refer more to MDCX or EQ? In the previous week, Medicus Pharma had 2 more articles in the media than Equillium. MarketBeat recorded 4 mentions for Medicus Pharma and 2 mentions for Equillium. Equillium's average media sentiment score of 0.59 beat Medicus Pharma's score of 0.58 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in MDCX or EQ? 27.1% of Equillium shares are held by institutional investors. 11.2% of Medicus Pharma shares are held by company insiders. Comparatively, 30.3% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is MDCX or EQ more profitable? Medicus Pharma has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -74.34% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A -380.03% -224.22% Equillium -19.62%-74.34%-46.75% Do analysts prefer MDCX or EQ? Medicus Pharma presently has a consensus price target of $23.50, suggesting a potential upside of 675.58%. Equillium has a consensus price target of $3.00, suggesting a potential upside of 757.14%. Given Equillium's higher probable upside, analysts clearly believe Equillium is more favorable than Medicus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable earnings & valuation, MDCX or EQ? Equillium has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/A-$11.16M-$1.16-2.61Equillium$41.10M0.30-$8.07M-$0.39-0.90 SummaryEquillium beats Medicus Pharma on 9 of the 14 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.50M$2.93B$5.55B$9.08BDividend YieldN/A2.41%5.25%4.02%P/E RatioN/A20.8528.2620.26Price / Sales0.30267.57411.94152.32Price / CashN/A42.1137.1257.67Price / Book0.657.638.045.49Net Income-$8.07M-$55.05M$3.19B$250.45M7 Day Performance7.03%8.43%3.62%4.79%1 Month Performance0.86%8.14%5.98%9.59%1 Year Performance-58.45%1.62%29.39%16.41% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium2.7282 of 5 stars$0.35+0.5%$3.00+757.1%-58.4%$12.50M$41.10M0.0040News CoverageGap DownMDCXMedicus Pharma2.2164 of 5 stars$3.40+0.6%$23.50+591.2%N/A$45.88MN/A-2.93N/AAnalyst ForecastGap UpHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070APLTApplied Therapeutics4.3367 of 5 stars$0.34+4.9%$6.10+1,717.6%-92.5%$45.30M$460K-0.7830PLURPluri3.4447 of 5 stars$5.79+0.2%$12.00+107.3%-7.5%$45.28M$330K-1.05150PRLDPrelude Therapeutics3.7369 of 5 stars$0.81+1.6%$4.50+457.8%-82.1%$44.82M$7M-0.48120Positive NewsMURAMural Oncology3.0732 of 5 stars$2.48-3.9%$12.00+383.9%-25.4%$44.55MN/A-0.32119ATNMActinium Pharmaceuticals2.8194 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230News CoveragePositive NewsSCLXScilex2.5645 of 5 stars$6.25-1.7%$455.00+7,180.0%-90.5%$44.21M$50.71M-0.2280Positive NewsGRCEGrace Therapeutics2.5705 of 5 stars$3.00-4.2%$12.00+300.0%N/A$43.28MN/A-3.37N/AGap DownXCURExicure1.4883 of 5 stars$6.47-4.6%N/A+2,101.0%$42.83M$500K-1.6950Positive NewsGap Down Related Companies and Tools Related Companies Medicus Pharma Competitors Nabriva Therapeutics Competitors Applied Therapeutics Competitors Pluri Competitors Prelude Therapeutics Competitors Mural Oncology Competitors Actinium Pharmaceuticals Competitors Scilex Competitors Grace Therapeutics Competitors Exicure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
